Search…

Lates News

24/04/2026

Every Economic AI News Flash, Guotai Junan Securities released a research report on April 24th, giving YTO Express (600233.SH) a "Buy" rating. The rating reasons mainly include: 1) the company's revenue is expected to grow steadily by 2025, with a narrowing decline in single ticket income starting from Q3; 2) profit capability is expected to start recovering in 2025 Q4; 3) profit capability is expected to continue to rise in 2026 Q1, expecting further release of the company's profit elasticity. (Daily Economic News)

Latest

3 m ago

Each AI Express, Southwest Securities released a research report on April 24th, giving Chongqing Road and Bridge (600106.SH) a "hold" rating. The rating reasons mainly include: 1) the annual toll revenue from road and bridge tolls is fully collected, stabilizing the company's foundation for continuous operation and development; 2) the company's holdings in Yufu Expressway and Chongqing Bank have both contributed good investment returns; 3) the company actively seeks opportunities for development in advanced semiconductor and information industries. (Daily Economic News)

3 m ago

According to the AI flash news, Southwest Securities released a research report on April 24, giving Satellite Petrochemical (002648.SZ) a "buy" rating with a target price of 34.32 yuan. The rating reasons mainly include: 1) integrated advantages highlighted, high-end and overseas layout accelerating; 2) continuous progress of high value-added projects, significant effects of overseas expansion; 3) continuous optimization of business structure, differential performance of core sectors. (Daily Economic News)

3 m ago

Silver continuous main contract fell 4% intraday, now reported at 18500.00 yuan.

3 m ago

Each AI express news, Southwest Securities released a research report on Kang Chen Pharmaceutical (603590.SH) on April 24. The main points include: 1) The effectiveness of marketing capability building continues to show, and the market competitiveness of core products continues to improve continuously; 2) Focus on innovative research and development, continuously enriching the matrix of innovative varieties; 3) KC1086 has great market potential and successfully obtained the new drug clinical research permission from the US FDA. (Daily Economic News)

3 m ago

Din Tai Fung has incurred a loss of 1.5 billion yuan in the past five years, and its affiliated company was recently forced to pay a debt of 290,000 yuan.

See all latest